Helus Pharma (Nasdaq: CYBN) to speak at H.C. Wainwright Neuro Perspectives
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Cybin Inc., operating commercially as Helus Pharma, filed a Form 6-K highlighting Helus Pharma’s participation in the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 15-16, 2026, where its Chief Medical Officer will join a fireside chat available on demand.
The filing also describes Helus Pharma as a clinical-stage company developing proprietary novel serotonergic agonists (NSAs) for mental health conditions, including HLP003 in Phase 3 for adjunctive treatment of major depressive disorder with U.S. FDA Breakthrough Therapy Designation and HLP004 in Phase 2 for generalized anxiety disorder, alongside an expanded NSA research portfolio and standard forward-looking statement cautions.
Positive
- None.
Negative
- None.
Key Terms
novel serotonergic agonists, Breakthrough Therapy Designation, Phase 3 clinical development, major depressive disorder, +2 more
6 terms
novel serotonergic agonists medical
"developing proprietary NSAs - novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways"
Breakthrough Therapy Designation regulatory
"HLP003, a proprietary NSA, in Phase 3 clinical development... that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration"
A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.
Phase 3 clinical development medical
"HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder"
Phase 3 clinical development is the large, late-stage testing of a medical treatment in diverse patient populations to confirm whether it works, to gather more safety information, and to compare it with current standard treatments. Think of it like a final dress rehearsal before a product’s public launch: regulators rely on Phase 3 results to decide approval, so clear success can sharply increase a product’s commercial value while failure can materially reduce a company’s prospects.
major depressive disorder medical
"Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation"
A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.
generalized anxiety disorder medical
"HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder"
Generalized anxiety disorder is a chronic mental health condition marked by persistent, excessive worry about everyday things that is hard to control and interferes with daily life. Think of it like a smoke alarm that stays on for weeks or months, making work, decision-making and productivity harder; for investors it matters because it drives demand for treatments, affects workforce performance and can influence regulatory scrutiny, clinical trial design and healthcare spending.
forward-looking statements regulatory
"Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June, 2026.
Commission File Number: 001-40673
Cybin Inc.
(Exact Name of Registrant as Specified in Charter)
100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F □ Form 40-F ⊠
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CYBIN INC. | ||||||||||||||
| (Registrant) | ||||||||||||||
| Date: | June 11, 2026 | By: | /s/ Greg Cavers | |||||||||||
| Name: | Greg Cavers | |||||||||||||
| Title: | Chief Financial Officer | |||||||||||||
EXHIBIT INDEX
| 99.1 | News Release dated June 11, 2026 | ||||
Helus Pharma to Participate in the H.C. Wainwright
7th Annual Neuro Perspectives Conference
NEW YORK & TORONTO – June 11, 2026 – Helus PharmaTM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Amir Inamdar, Helus Pharma’s Chief Medical Officer, will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference taking place June 15-16, 2026.
The fireside chat will be available on demand beginning on Monday, June 15 at 7:00 a.m. EDT.
To register for the webcast, click here. A replay will be available on the Events & Presentations page of Helus Pharma’s investor relations website.
About Helus Pharma
Helus Pharma™, the commercial operating name of Cybin Inc. (the “Company” or “Helus Pharma”) is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs - novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in Phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The Company operates in Canada, the United States, the United Kingdom, and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube and Instagram. Helus PharmaTM is a trademark of Cybin Corp.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, “forward-looking statements”) and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “potential”, “possible”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the NSA market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2025, and the Company’s annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov/edgar. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
The Company makes no medical, treatment or health benefit claims about the Company’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding NSAs or HLP003, HLP004 and other programs of the Company. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of NSAs, HLP003, HLP004 or other programs of the Company can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Helus Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.
Neither Cboe Canada, nor the Nasdaq Global Market stock exchange, have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.
Investor Contact:
Matthew Beck
astr partners
Managing Partner
(917) 415-1750
Matthew.beck@astrpartners.com
George Tziras
Chief Business Officer
Helus Pharma
1-866-292-4601
irteam@helus.com – or – media@helus.com
Media Contact:
Johnny Tokarczyk
RXMD
Public Relations Director
jtokarczyk@rxmedyn.com
(914) 772-7562
FAQ
What does Cybin Inc. (CYBN) announce in this Form 6-K?
Cybin Inc., through its Helus Pharma brand, reports that its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright 7th Annual Neuro Perspectives Conference on June 15-16, 2026, highlighting ongoing engagement with the neuroscience and investor communities.
What is HLP003 in Helus Pharma’s pipeline for Cybin Inc. (CYBN)?
HLP003 is a proprietary novel serotonergic agonist in Phase 3 clinical development as an adjunctive treatment for major depressive disorder. It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, signaling regulatory recognition of its potential based on early clinical data.
What is HLP004 and which condition is Cybin Inc. (CYBN) targeting?
HLP004 is another proprietary novel serotonergic agonist being developed by Helus Pharma in Phase 2 clinical development for generalized anxiety disorder. It forms part of a broader portfolio of investigational NSAs intended to improve treatment options for significant mental health conditions globally.
When is Helus Pharma’s presentation at the H.C. Wainwright Neuro Perspectives Conference?
Helus Pharma’s fireside chat will be available on demand beginning Monday, June 15, 2026, at 7:00 a.m. EDT during the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference, which runs from June 15-16, 2026, with a replay accessible via its investor relations website.
What forward-looking statement cautions does Cybin Inc. (CYBN) provide?
Cybin notes that statements about its plans, drug discovery platforms and treatment regimens are forward-looking and subject to risks and uncertainties. It highlights macroeconomic factors, market conditions, regulation, disease outbreaks and risk factors in its MD&A and annual information form as potential drivers of differing outcomes.
Has Helus Pharma obtained regulatory approval for NSAs like HLP003 and HLP004?
The company states that the U.S. Food and Drug Administration, Health Canada and similar authorities have not evaluated claims regarding its NSAs or programs. It emphasizes that efficacy is unconfirmed, rigorous clinical trials are needed, and lack of required approvals could materially affect its performance and operations.